BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOTBiotechnology
-$0.03 today
- Market cap
- $144.85M
- Beta
- 0.29
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$4.95
Volume 0.58M
Average 0.37M
BBOT Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
BridgeBio Oncology Therapeutics Inc.NASDAQ: BBOT
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $39.8M rose 92.9% year over year, ahead of the +74.2% change in trailing-twelve-month research & development. Sequentially, it rose 4.5% from the prior quarter.
Context
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +92.9% holds above the trailing-twelve-month pace of +74.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 121.2M USD
- Year-over-year change
- +65.8%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 121.2M | +65.8% |
| FY2024 | 2024-12-31 | 73.11M | +29.9% |
| FY2023 | 2023-12-31 | 56.29M | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Research & Development vs competitors
How BBOT compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +74.2% is the highest of 10, against a peer median of +10.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Aug 2026 | $331.95M USD | +10.2% | +18.6% | 47.3% | |
| LTM Jun 2026 | $255.77M USD | +11.4% | +6.3% | 243.6% | |
| LTM Sep 2026 | $208.43M USD | +23.6% | -12.0% | — | |
| LTM Sep 2026 | $152.48M USD | +14.3% | +7.7% | — | |
BBOTBridgeBio Oncology Therapeutics Inc. | LTM Mar 2026 | $140.37M USD | +74.2% | — | — |
SEPNSepterna, Inc. | LTM Sep 2026 | $132.66M USD | +56.0% | — | 137.8% |
| LTM Mar 2026 | $128.65M USD | -23.4% | +15.3% | 55.4% | |
| LTM Mar 2026 | $62.83M USD | +2.1% | +8.2% | 44.7% | |
| LTM Mar 2026 | CHF 56.48M CHF | +0.9% | +34.9% | 11206.4% | |
| LTM Mar 2026 | $31.37M USD | -7.3% | -22.9% | 15.3% | |
| Peer median (excluding BBOT) | — | +10.2% | +8.0% | 55.4% | |
Competitors are the stored peer set for BBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 0 | 0 | 56.29M | 73.11M | 121.2M |
| Selling, General & Admin | 43.36K | 3.52K | 8.49M | 7.76M | 24.62M |
| Operating Expenses | 43.36K | 3.52K | 64.77M | 80.86M | 145.82M |
| Depreciation & Amortization | 74.33K | 3.52K | 92K | 208K | 610K |
| EBITDA | (43.36K) | (3.52K) | (64.68M) | (80.66M) | (145.21M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (43.36K) | (3.52K) | (64.77M) | (80.86M) | (145.82M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 72K | 8.46M | 11.34M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 0 | 0 | 72K | 8.18M | 11.78M |
| Income Before Tax | (43.36K) | (3.52K) | (64.7M) | (74.28M) | (134.04M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (43.36K) | (3.52K) | (64.7M) | (74.28M) | (134.04M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.00) | 0.00 | (3.16) | 0.46 | (4.30) |
| EPS (Diluted) | (0.00) | (0.00) | (3.16) | 0.46 | (4.30) |
| Weighted Avg Shares | 20.49M | 20.49M | 20.49M | 16.64M | 31.14M |
| Weighted Avg Shares (Diluted) | 20.49M | 20.49M | 20.49M | 16.64M | 31.14M |
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
Intrinsic Alpha fair value
Locked
Current Price
$1.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.